Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Click ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Not only adults, nasal polyps can also occur in children. Polyps are an inflammation of the nasal membranes and sinuses that ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

Suggested remit: To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for previously treated severe nasal polyps. As you will be aware, the Department for ...

Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.